(Q34154200)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

31 July 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. (English)

1 reference

31 July 2017

1 reference

Bilal A Azakir

1

1 reference

31 July 2017

Sabrina Di Fulvio

series ordinal

2

1 reference

31 July 2017

Jochen Kinter

series ordinal

3

1 reference

31 July 2017

Michael Sinnreich

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

Journal of Biological Chemistry

31 July 2017

1 reference

31 July 2017

287

1 reference

31 July 2017

13

1 reference

31 July 2017

10344-10354

1 reference

describes a project that uses

31 July 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3323038/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Dysferlin interacts with tubulin and microtubules in mouse skeletal muscle

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Therapeutic exon skipping for dysferlinopathies?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Protein-misfolding diseases and chaperone-based therapeutic approaches

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Development of the proteasome inhibitor Velcade (Bortezomib).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Defective membrane repair in dysferlin-deficient muscular dystrophy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Expression of the E6 and E7 genes of human papillomavirus (HPV16) extends the life span of human myoblasts

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Degradation of CFTR by the ubiquitin-proteasome pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro".

5 July 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Analysis of the DYSF mutational spectrum in a large cohort of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Novel DYSF mutations in Thai patients with distal myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

In vivo and in vitro dysferlin expression in human muscle satellite cells

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3323038

Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B

28 October 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M111.329078

The potential of proteasome inhibitors in cancer therapy

21 January 2018

1 reference

12 December 2020

Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer

1 reference

12 December 2020

The synthesis and distribution of desmin and vimentin during myogenesis in vitro

1 reference

12 December 2020

Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies

1 reference

12 December 2020

Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice

1 reference

12 December 2020

Local dystrophin restoration with antisense oligonucleotide PRO051

1 reference

12 December 2020

Identifiers

DOI

10.1074/JBC.M111.329078

1 reference

31 July 2017

1 reference

31 July 2017

1 reference